OBJECTIVES: Retinal prosthesis is the only approved treatment of blindness caused by a rare degenerative disorder retinitis pigmentosa (RP). The objective of this budget impact analysis is to estimate the budgetary impact of using FDA and CE approved Argus II Retinal Prosthesis System in patients with severe to profound RP in Germany. METHODS: We evaluated the budget impact of introduction of retinal prosthesis using an Excel based model over a five-year time horizon. The Model calculated patients eligible for retinal prosthesis based on the prevalence of RP and total population. A very conservative uptake of the retinal prosthesis was assumed ranging from 0.2% to 1.01% over the time horizon. The model forecasted expenditures resulting from the reimbursement of retinal prosthesis to the German health care system compared to a reference scenario of standard care. Costs and the corresponding range of net impact were estimated in sensitivity analyses. RESULTS: The costs incurred by the retinal prosthesis from year 2015 to 2019 were increased from 2 million to 10 million Euros while the standard care costs decreased from 153 million to 149 million. Total annual costs for the treatment mix was 154.8 million for 2015, 155.5 million for 2016, 156.4 million for 2017, 157.8 million for 2018 and 159.7 million for 2019. The Model predicted vision improvement in 187 RP patients over the period of 5 years and was robust to all variables tested in the sensitivity analyses. CONCLUSIONS: The budget impact of introduction of the innovative retinal prosthesis as a treatment option for RP is not high and reduction in standard care costs could offset it partially. Retinal prosthesis could have a considerable societal and individual impact as it will help patients to navigate better at home, be more independent and have the pleasure of seeing things that the rest of us take for granted.